

Maja Guberina

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8721285/publications.pdf>

Version: 2024-02-01

15
papers

196
citations

1478505

6
h-index

1058476

14
g-index

16
all docs

16
docs citations

16
times ranked

336
citing authors

#	ARTICLE	IF	CITATIONS
1	Standardized Uptake Decrease on [18F]-Fluorodeoxyglucose Positron Emission Tomography After Neoadjuvant Chemotherapy Is a Prognostic Classifier for Long-Term Outcome After Multimodality Treatment: Secondary Analysis of a Randomized Trial for Resectable Stage IIIA/B Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 2526-2533.	1.6	40
2	Independent validation of a new reirradiation risk score (RRRS) for glioma patients predicting post-recurrence survival: A multicenter DTK/ROG analysis. <i>Radiotherapy and Oncology</i> , 2018, 127, 121-127.	0.6	37
3	Re-irradiation of recurrent gliomas: pooled analysis and validation of an established prognostic score report of the Radiation Oncology Group (ROG) of the German Cancer Consortium (DKTK). <i>Cancer Medicine</i> , 2018, 7, 1742-1749.	2.8	34
4	Comprehensive Analysis of Tumour Sub-Volumes for Radiomic Risk Modelling in Locally Advanced HNSCC. <i>Cancers</i> , 2020, 12, 3047.	3.7	19
5	Impact of EBUS-TBNA in addition to [18F]FDG-PET/CT imaging on target volume definition for radiochemotherapy in stage III NSCLC. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2894-2903.	6.4	11
6	Pretreatment metabolic tumour volume in stage IIIA/B non-small-cell lung cancer uncovers differences in effectiveness of definitive radiochemotherapy schedules: analysis of the ESPATUE randomized phase 3 trial. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1439-1447.	6.4	8
7	Patterns of cervical lymph node metastasis in supraglottic laryngeal cancer and therapeutic implications of surgical staging of the neck. <i>European Archives of Oto-Rhino-Laryngology</i> , 2021, 278, 5021-5027.	1.6	7
8	Effectiveness of durvalumab consolidation in stage III non-small-cell lung cancer: focus on treatment selection and prognostic factors. <i>Immunotherapy</i> , 2022, 14, 927-944.	2.0	7
9	ERCC2 gene single-nucleotide polymorphism as a prognostic factor for locally advanced head and neck carcinomas after definitive cisplatin-based radiochemotherapy. <i>Pharmacogenomics Journal</i> , 2021, 21, 37-46.	2.0	6
10	Patterns of nodal spread in stage III NSCLC: importance of EBUS-TBNA and 18F-FDG PET/CT for radiotherapy target volume definition. <i>Radiation Oncology</i> , 2021, 16, 176.	2.7	6
11	Prognostic Value of Postinduction Chemotherapy Volumetric PET/CT Parameters for Stage IIIA or IIIB Non-Small Cell Lung Cancer Patients Receiving Definitive Chemoradiotherapy. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1684-1691.	5.0	5
12	Analyses of molecular subtypes and their association to mechanisms of radioresistance in patients with HPV-negative HNSCC treated by postoperative radiochemotherapy. <i>Radiotherapy and Oncology</i> , 2022, 167, 300-307.	0.6	5
13	Biomarker signatures for primary radiochemotherapy of locally advanced HNSCC – Hypothesis generation on a multicentre cohort of the DTK-ROG. <i>Radiotherapy and Oncology</i> , 2022, 169, 8-14.	0.6	5
14	Development and validation of a 6-gene signature for the prognosis of loco-regional control in patients with HPV-negative locally advanced HNSCC treated by postoperative radio(chemo)therapy. <i>Radiotherapy and Oncology</i> , 2022, 171, 91-100.	0.6	4
15	A Novel 2-Metogene Signature to Identify High-Risk HNSCC Patients amongst Those Who Are Clinically at Intermediate Risk and Are Treated with PORT. <i>Cancers</i> , 2022, 14, 3031.	3.7	2